Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
-
Publication number: 20150023956Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis III (MPS-III). The fusion antibodies provided herein comprise N-sulfoglucosamine sulfohydrolase (SGSH), alpha-N-acetylgulcosaminidase (NAGLU), heparin-alpha-glucosaminide N-acetyltransferase (HGSNAT), or N-acetylglucosamine-6-sulfatase (GNS). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.Type: ApplicationFiled: May 19, 2014Publication date: January 22, 2015Applicant: ArmaGen Technologies, Inc.Inventors: William M. PARDRIDGE, Ruben J. BOADO
-
Publication number: 20150024456Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.Type: ApplicationFiled: July 30, 2014Publication date: January 22, 2015Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
-
Publication number: 20150024455Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: July 17, 2014Publication date: January 22, 2015Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20150023963Abstract: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.Type: ApplicationFiled: June 20, 2014Publication date: January 22, 2015Applicant: Ablynx N.V.Inventors: Hilde Stals, Veronique De Brabandere, Peter Schotte
-
Publication number: 20150024459Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.Type: ApplicationFiled: October 3, 2014Publication date: January 22, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20150023987Abstract: The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.Type: ApplicationFiled: January 27, 2012Publication date: January 22, 2015Applicant: PURDUE RESEARCH FOUNDATIONInventor: Lawrence E. Hem
-
Publication number: 20150024458Abstract: Disclosed herein are methods and compositions dock and lock (DNL) complexes comprising an AD moiety selected from an AKAP protein and a DDD moiety selected from a protein kinase A regulatory subunit. Also disclosed are fusion proteins comprising an AD moiety or DDD moiety attached to an effector moiety. The DDD moieties form dimers that bind to the AD moiety to form the DNL complexes. The effector moieties may be selected from a wide range of known effector moieties that produce one or more physiological effects, including but not limited to cell death. The DNL complexes may further comprise one or more diagnostic and/or therapeutic agents. The DNL complexes are of use for treating and/or diagnosing a variety of diseases or conditions.Type: ApplicationFiled: October 1, 2014Publication date: January 22, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20150024460Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Inventors: Anthony Quinn, Alex J Harvey, Zhinan Xia
-
Publication number: 20150024457Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.Type: ApplicationFiled: September 5, 2014Publication date: January 22, 2015Inventors: Susan E. Brophy, Bailin Tu, Joan D. Tyner, Dagang Huang, Robert N. Ziemann
-
Publication number: 20150024417Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic ehrlichiosis.Type: ApplicationFiled: August 1, 2014Publication date: January 22, 2015Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
-
Publication number: 20150024442Abstract: Provided are fusion proteins of diacylglycerol acyltransferase (DGAT) polypeptides fused to at least one heterologous intracellular localization domain, such as a bacterial membrane-targeting domain, modified photosynthetic microorganism that comprise such fusion proteins, and related methods for improving the production of lipids by photosynthetic microorganisms, including lipids such as triglycerides, fatty acids, and wax esters.Type: ApplicationFiled: March 4, 2013Publication date: January 22, 2015Applicant: Matrix Genetics, LLCInventors: James Roberts, Kimberly Marie Kotovic, Jason W. Hickman, Tracey Jurista, Michael Carleton
-
Patent number: 8936911Abstract: Methods, Compositions, and Systems are provided for obtaining polymerase-template complex mixtures with improved levels of active polymerase. In some aspects, methods are described in which a polymerase-template complex is exposed to reaction conditions in which a complementary strand to the template is produced. The extended reaction mixture is purified, for example by gel filtration chromatography to produce a mixture of polymerase-template complex having a higher active fraction. This purified mixture can be used for further analyses including single molecule sequencing.Type: GrantFiled: September 15, 2011Date of Patent: January 20, 2015Assignee: Pacific Biosciences of California, Inc.Inventors: Lei Sun, Insil Park
-
Publication number: 20150017189Abstract: The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.Type: ApplicationFiled: January 18, 2013Publication date: January 15, 2015Inventors: Carston R. Wagner, Jae Chul Lee, Sidath C. Kumarapperuma
-
Publication number: 20150017098Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.Type: ApplicationFiled: October 20, 2011Publication date: January 15, 2015Inventors: Junji Kato, Rishu Takimoto
-
Publication number: 20150017173Abstract: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.Type: ApplicationFiled: August 28, 2014Publication date: January 15, 2015Applicant: Incyte CorporationInventors: Y. Tom Tang, Preeti G. Lal, Jennifer L. Jackson, Henry Yue, Karl J. Guegler, Neil C. Corley, Olga Bandman, Chandra S. Arvizu, Gina A. Gorgone Simone, Matthew R. Kaser, Mariah R. Baughn, Janice K. Au-Young
-
Patent number: 8932717Abstract: Provided are a use of a lipolytic enzyme for forming anti-fingerprint coating, a method of forming anti-fingerprint coating including treating a substrate with a composition comprising the lipolytic enzyme, a substrate including the anti-fingerprint coating formed by the same method, and a product including the same. The anti-fingerprint coating can reduce contamination of display devices, appearances of electronic devices or building materials by fingerprints.Type: GrantFiled: September 17, 2010Date of Patent: January 13, 2015Assignee: LG Chem, Ltd.Inventors: Eun Jeong Lee, Young Jun Hong, Hyeon Choi, Taek Ho Yang
-
Patent number: 8933396Abstract: Quantitation of analytes, including but not limited to peptides, polypeptides, and proteins, in mass spectrometry using a labeled peptide coupled to a reporter, and a universal reporter.Type: GrantFiled: July 7, 2011Date of Patent: January 13, 2015Assignee: Thermo Fisher Scientific GmbHInventors: Joel Louette, John Charles Rogers, Scott M. Peterman, Bruno Domon, Elodie Duriez
-
Patent number: 8932586Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: GrantFiled: September 5, 2012Date of Patent: January 13, 2015Assignee: Intrexon CorporationInventors: Timothy David Jones, Francis Joseph Carr
-
Publication number: 20150010529Abstract: Modified PH20 hyaluronidase polypeptides that exhibit stability and activity under thermal stress conditions are provided. Also provided are compositions and formulations and uses thereof.Type: ApplicationFiled: July 3, 2014Publication date: January 8, 2015Inventor: Ge Wei
-
Publication number: 20150011417Abstract: The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding.Type: ApplicationFiled: March 6, 2013Publication date: January 8, 2015Inventors: Jan Tavernier, Samuel Lievens
-
Publication number: 20150010494Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventors: Gord Adamson, David Bell, Steven Brookes
-
Publication number: 20150010947Abstract: Methods and systems for creating a genetic construct, a protein, and a polymer comprising a domain swapping module. A domain swapping module is a fusion protein in which a lever protein, which has a long amino (N) to carboxy (C) terminal distance, is inserted into a surface loop of an assembler protein, thereby stretching the assembler protein and splitting it into two fragments held apart by the lever so that they cannot rejoin. If the assembler protein is split at the proper location, the fragments will recombine with their respective counterparts from either one or more different—but similarly-split—assembler proteins.Type: ApplicationFiled: December 27, 2012Publication date: January 8, 2015Applicant: The Research Foundation For The State University Of New YorkInventors: Stewart Loh, Jeung-hio Ha, Diana Mitrea
-
Publication number: 20150011433Abstract: Multi-biotinylated reactants are provided which can be used in divalent complexes for various applications such as colocalization, labeling, immobilization, and purification. Methods for constructing, purifying, and using the bis-biotinylated reactants are also provided. In certain embodiments, two bis-biotinylated reactants are bound to a single streptavidin tetramer to provide a complex having a 1:1 stoichiometry with respect to the bis-biotinylated reactants.Type: ApplicationFiled: June 12, 2014Publication date: January 8, 2015Applicant: Pacific Biosciences of California, Inc.Inventors: Erik Miller, Satwik Kamtekar, Keith Bjornson, Jeremiah Hanes
-
Publication number: 20150010522Abstract: The present invention provides a site-directed mutated arginase and the preparation method thereof, and the use of said site-directed mutated arginase in preparing a medicament for treating an arginase-related disease. The present invention also provides a site-directed pegylated arginase and the preparation method thereof, and the use of said pegylated arginase in preparing a medicament for treating an arginase-related disease.Type: ApplicationFiled: December 23, 2012Publication date: January 8, 2015Inventors: Ning Man Cheng, Li Chen
-
Publication number: 20150010570Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.Type: ApplicationFiled: June 4, 2014Publication date: January 8, 2015Inventors: Richard J. Bucala, Lin Leng, Christine N. Metz
-
Publication number: 20150011524Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.Type: ApplicationFiled: September 19, 2014Publication date: January 8, 2015Inventors: Larry SUTTON, Sophia YU
-
Patent number: 8926982Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.Type: GrantFiled: May 28, 2010Date of Patent: January 6, 2015Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
-
Publication number: 20150004099Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20150004667Abstract: The present invention is generally directed to functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention provides a graphene substrate. The substrate comprises edge and non-edge regions, and organic or inorganic molecules are bound to the edge regions of the substrate. The organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm.Type: ApplicationFiled: May 23, 2014Publication date: January 1, 2015Applicant: NANOTECH BIOMACHINES, INC.Inventors: Jeffrey Alan McKinney, William Emerson Matinez
-
Patent number: 8920807Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: GrantFiled: November 2, 2010Date of Patent: December 30, 2014Assignees: The Regents of the University of California, The United States of America Represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Patent number: 8921085Abstract: Manufacturing methods and compositions are described for production of self-contained microfluidic cartridge devices with on-board reagents for molecular biological testing. Sensitive reagents are stored in dry form without lyophilization or freezing, and reconstituted at the point of use with either a biological sample or a sample eluate at the point of use. Manufacturing methods include sheet and roll fabrication processes where the reagents are printed in place and sealed within individual microfluidic cartridges before gel vitrification.Type: GrantFiled: December 12, 2011Date of Patent: December 30, 2014Assignee: Micronics, Inc.Inventors: C. Frederick Battrell, Denise Maxine Hoekstra, Joan Haab, John R. Williford, Sabrina N. Gates, Elizabeth R. Leber, Isaac Sprague
-
Publication number: 20140377837Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.Type: ApplicationFiled: June 9, 2014Publication date: December 25, 2014Inventors: Brian AGNEW, Kyle Gee, Schuyler Corry
-
Publication number: 20140377838Abstract: Compositions and methods for stabilizing biomolecules are disclosed. Specifically, the compositions include novel homopolymers or copolymers containing trehalose side chains conjugated to biomolecules. When such homopolymers or copolymers are placed in close proximity to biomolecules, such as proteins, the homopolymers or copolymers protect and/or stabilize the biomolecule. The compositions and methods may be suitable for use in various industries such as healthcare (pharmaceuticals), molecular biology, biofuels, paper, personal care, detergent, photographic, rubber, brewing, dairy and food processing industries.Type: ApplicationFiled: January 25, 2013Publication date: December 25, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Heather D. Maynard, Rock J. Mancini, Juneyoung Lee, En-Wei Lin
-
Publication number: 20140377289Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: ApplicationFiled: September 9, 2014Publication date: December 25, 2014Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Publication number: 20140377784Abstract: The invention provides compositions, methods, and kits diagnosing, monitoring, and otherwise characterizing a myopathy and for detecting the presence of autoantibodies in a biological sample.Type: ApplicationFiled: May 21, 2014Publication date: December 25, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Livia A. Casciola-Rosen, Lisa Christopher-Stine, Andrew Mammen, Antony Rosen
-
Publication number: 20140377810Abstract: Fusion proteins comprising a single strand DNA binding protein and a nucleic acid polymerase (e.g. DNA polymerase or reverse transcriptase). These high fidelity proteins are suitable for use in nucleic acid amplification methods, including the polymerase chain reaction (PCR).Type: ApplicationFiled: August 4, 2014Publication date: December 25, 2014Inventors: Jun LEE, Robert Potter, David Mandelman
-
Publication number: 20140377836Abstract: The present invention relates to a crystal. In particular the present invention relates to a crystal of the N-domain of ACE protein. The present invention also relates to methods, processes, domain specific modulators, pharmaceutical compositions and uses of the N-domain crystal and the structure co-ordinates thereof.Type: ApplicationFiled: June 5, 2014Publication date: December 25, 2014Applicants: UNIVERSITY OF BATH, UNIVERSITY OF CAPE TOWNInventors: Ravi Acharya, Edward Sturrock
-
Publication number: 20140377243Abstract: The present invention relates to a cell permeable fusion protein for strengthening regenerative potential of stem cells, and more particularly to a cell permeable fusion protein for strengthening regenerative potential of stem cells for stimulating the differentiation of stem cells, inhibiting apoptosis, maintaining the functionality of stem cells and restoring the stress-inhibited functionality of stem cells.Type: ApplicationFiled: December 16, 2011Publication date: December 25, 2014Applicants: NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO, LTD., SEOUL NATIONAL UNIVERSITY R AND DB FOUNDATIONInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee
-
Publication number: 20140377827Abstract: The present invention provides hybrid polypeptides having cellobiohydrolase activity. The present invention also provides polynucleotides encoding the hybrid polypeptides; nucleic acid constructs, vectors and host cells comprising the polynucleotides; and processes of using the hybrid polypeptides.Type: ApplicationFiled: December 21, 2012Publication date: December 25, 2014Inventors: Ye Liu, Tarana Shaghasi
-
Publication number: 20140377216Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and at least one domain (b) which is a sequence of a cytolytic effector peptide forming pores in the cell membrane, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: December 22, 2012Publication date: December 25, 2014Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Zerek, Piotr Kamil Rozga
-
Publication number: 20140370016Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: July 31, 2014Publication date: December 18, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20140369926Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: June 19, 2014Publication date: December 18, 2014Inventors: J. Andrew BRISTOL, Judith A. KANTOR
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20140369986Abstract: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.Type: ApplicationFiled: May 15, 2014Publication date: December 18, 2014Applicant: GangaGen, Inc.Inventors: Sriram Padmanabhan, Vivek Daniel Paul, R.Sanjeev Saravanan, Bharathi Sriram
-
Publication number: 20140369960Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via an amine group; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two amine groups; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via amine groups in saiType: ApplicationFiled: July 28, 2014Publication date: December 18, 2014Inventors: Stephen James BROCCHINI, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
-
Patent number: 8911731Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.Type: GrantFiled: July 6, 2012Date of Patent: December 16, 2014Assignee: Janssen Pharmaceutica NVInventors: Marc Hubert Mercken, Marianne Borgers, Marc Maria Pierre Pelagie Vandermeeren, Bianca Julia J Van Broeck
-
Patent number: 8911976Abstract: The invention relates to an enzyme stabilizer comprising a lignin derivative produced by reaction between lignin and a hydrophilic compound, and to a method of saccharifying lignocellulosic biomass which employs the enzyme stabilizer. According to the invention it is possible to accomplish effective saccharification of cellulosic biomass with saccharifying enzymes, by enhancing saccharifying enzyme activity and preventing nonspecific adsorption of saccharifying enzyme onto substrate.Type: GrantFiled: March 7, 2011Date of Patent: December 16, 2014Assignee: Forestry and Forest Products Research InstituteInventors: Yasumitsu Uraki, Harumi Honma, Tatsuhiko Yamada, Satoshi Kubo, Masanobu Nojiri
-
Publication number: 20140360403Abstract: A method for producing organic-inorganic composite materials includes at least one biomineralising protein and/or polypeptide-encoding recombinant polynucleotide being introduced into at least one host cell, preferably from the class of slime moulds, and the expressed protein and/or polypeptide influencing the formation of inorganic particles in an extracellular matrix of the host cell.Type: ApplicationFiled: December 19, 2012Publication date: December 11, 2014Inventors: Ingrid Weiss, Eva Weber, Magdalena Eder, Eduard Arzt, Andreas Simon Schneider
-
Publication number: 20140363873Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: May 8, 2014Publication date: December 11, 2014Applicant: Genentech, Inc.Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
-
Patent number: 8906379Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 20, 2012Date of Patent: December 9, 2014Assignee: Genzyme CorporationInventor: James Stefano